named programs · 2 · from sources
What they call their work
Scientific Article Summaries on OUD Treatment
Curates and disseminates summaries of peer-reviewed research on medications for opioid use disorder to educate the public and professionals about effective treatments and combat misinformation.
Stigma Reduction Advocacy
Advocates for policy and cultural change to eliminate stigma against medication-based treatment for opioid use disorder, promoting methadone and buprenorphine as standard of care.
activities · 5 groups
What they do
-
Substance Use Policy Advocacy & Public Education 3 activities
- Advocacy to reduce stigma and improve access to medication treatment for opioid use disorderWorks to change public attitudes and institutional practices toward individuals with substance use disorders, advocating for expanded access to medication treatment in correctional settings and promoting medication treatment as a life-saving intervention to reduce opioid overdose deaths.
- Education to combat institutional stigmatization of MOUDProvides education and resources to address systemic stigma against medication treatment for opioid use disorder within institutions, including healthcare and legal systems.
- Support for medication-assisted treatment (MAT) centersProvides support to MAT centers, such as one in South Philadelphia, to address stigma and rising overdose rates through education and resource sharing.
-
-
Community Recovery Awareness Events 1 activity
- Hosting virtual events to recognize achievements and reduce stigmaHosts an annual virtual recognition event and monthly virtual meetings to highlight progress in addiction treatment and reduce stigma, including themed events such as “Voice of Hope” on stigma and harm reduction.
-
-
Charity Event Organization 1 activity
- Organization and promotion of virtual fundraising eventsHosts annual virtual fundraiser events such as “Break the Silence” breakfast to support organizational activities and raise awareness about opioid use disorder treatment.
-
-
Disease-Specific Clinical & Patient Education 1 activity
- Production and distribution of educational materials on medication treatment for opioid use disorderProduces and disseminates brochures, videos, social media content, and buttons to educate providers, policymakers, and the public about medication for opioid use disorder (MOUD), including hard-copy distribution upon request and outreach across community, medical, and legal systems.
-
-
Uncategorized 2 activities
- Collection and dissemination of lived-experience storiesMaintains and shares a collection of video stories from individuals with lived experience of opioid use disorder and medication treatment to humanize and destigmatize recovery.
- Research on opioid use disorder treatment policies and practicesConducts and publishes research on medication treatment for opioid use disorder, including studies on telehealth implementation, take-home medication policies during COVID-19, survey-based assessments of MOUD knowledge dissemination, and critiques of stigmatizing terminology in the field.
-
financials · form 990EZ · fy2025
revenue
Total revenue$56K
Contributions & grants$56K100%
Program service revenue——
Investment income$60%
Other revenue—
expenses
Total expenses$15K
Program expenses—
Admin / overhead—
Fundraising—
Salaries & benefits—
Grants paid out—
balance sheet
Total assets$113K
Cash—
Investments—
Liabilities—
Net assets$113K
5 years on record · 2021–2025 · YoY revenue +2.9%
leadership · form 990 part vii · fy2025
Who runs it
board members · 7
- BOB KRAUSS — DIRECTOR
- BRENDA DAVIS MSW — DIRECTOR
- GIDEON RABINO — DIRECTOR
- JORDANA ALFORD — DIRECTOR
- LORETTA FINNEGAN MD - NIDA — DIRECTOR
- MARIA PASCERI — DIRECTOR
- VALENTIN BONILLA JR PA — DIRECTOR
relationships · 22
Who they work with
- AATOD Partner — Collaborates on clinical reports and publications related to methadone treatment.
- AATOD Partner — Participated in the AATOD 2024 Conference, indicating collaboration or shared focus on addiction treatment and stigma reduction.
- American Association for the Treatment of Opioid Dependence (AATOD) Network — Conducted surveys and exhibited at AATOD conferences to assess awareness and dissemination of MOUD-related anti-stigma materials.
- American Society of Addiction Medicine Network — Referenced as a professional body whose guidelines support medication treatment for opioid use disorder without requiring psychosocial treatment as a precondition.
- David Novick, MD Partner — Longtime colleague of Dr. Miriam Adelson, presenting the award during the recognition event.
- Dr. Miriam Adelson Partner — Honoree at the 5th Annual Virtual Recognition Event for her contributions to addiction treatment and research.
- Dr. Yngvild Olsen Partner — Guest speaker at the event and Director of the Center for Substance Abuse Treatment (CSAT), providing federal perspective on substance use.
- End Overdose NY Partner — Steven Rabinowitz, a member of SSN's Board of Directors, serves on the advisory group for End Overdose NY.
- Grants Partner — Internal committee of Stop Stigma Now focused on grant-related activities.
- Joe “Yuseff” Wilson Partner — Person with lived experience who shared a personal recovery story at the event.
- Legal Action Center Partner — Cited as a source documenting discrimination against people using medication for opioid use disorder in recovery settings.
- Legal Action Center Partner — Honored Paul Samuels, director and president of the Legal Action Center, at the 2023 virtual fundraiser breakfast.
- National Academies of Sciences, Engineering, and Medicine Partner — References findings from the National Academies report on medications for opioid use disorder.
- National Association of Drug Court Professionals (NADCP) Network — Distributed surveys and shared anti-stigma materials at NADCP conferences to improve understanding of MOUD among drug court professionals.
- National Institute on Drug Abuse Government — Cited as a key authority supporting the efficacy of medication for opioid use disorder and referenced in organizational advocacy.
- National Institute on Drug Abuse Government — Cites statements from the Director of NIDA to support the effectiveness of medications for opioid use disorder.
- New York University Partner — Collaborated on a study examining the impact of COVID-19 on opioid treatment programs, including changes in take-home medication and telehealth policies.
- Our Jewish Recovery Partner — Steven Rabinowitz, a member of SSN's Board of Directors, serves on the advisory group for Our Jewish Recovery.
- Substance Abuse and Mental Health Services Administration Government — Referenced for its regulatory stance that patient refusal of counseling should not preclude access to medication for opioid use disorder.
- Virginia Commonwealth University Partner — Collaborating institution developing new formulations of LAAM, with SSN advocating for clinical trials of these formulations.
- World Health Organization Network — Referenced as a global authority affirming that psychosocial services should not be a condition for receiving pharmacological treatment for opioid dependence.
- info@stopstigmanow.org Partner — Point of contact for requesting brochure shipments and organizational outreach.
strategies · 5
How they approach the work
Named approaches extracted from this org’s sources. Where others share an approach, follow it to see the full set of orgs running it.
- Medication-First Treatment Modelmethodology: Medication FirstBy prioritizing FDA-approved medications as the foundation of care for opioid use disorder, we produce higher retention and better health outcomes because clinical evidence shows medications are the most effective intervention for moderate to severe OUD, especially when psychosocial services are offered as adjuncts rather than prerequisites.
- Outpatient-First Expansion Based on Treatment Efficacymethodology: outpatient-first expansionBy expanding access to outpatient medication for opioid use disorder rather than prioritizing residential treatment, we improve outcomes because evidence shows medication delivery—not treatment setting—is the key factor in preventing overdose deaths.
- Public Health Approach to Stigma as a Treatment Barriermethodology: stigma-reduction-for-treatment-accessBy framing stigma as a lethal public health barrier, we prioritize systemic interventions that increase access to evidence-based treatments because reducing stigma—especially around medications—is essential to preventing overdose deaths and improving treatment uptake.
- Reduced-Restriction Treatment Protocolsmethodology: reduced-restriction treatment modelBy advocating for less restrictive treatment models—including expanded take-home doses and telehealth—we reduce patient burden and stigma, thereby increasing treatment adherence because reduced structural barriers make sustained engagement more feasible.
- Stigma Reduction Through Language and Educationmethodology: language-based stigma reductionBy changing public and institutional language and promoting education around substance use disorders, we reduce stigma and increase treatment engagement because language shapes perception and influences whether individuals seek or receive care.